NASDAQ:VCEL Vericel - VCEL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. $29.37 +0.40 (+1.38%) (As of 03/27/2023 03:33 PM ET) Add Compare Share Share Today's Range$28.92▼$29.6950-Day Range$27.03▼$31.3452-Week Range$17.30▼$41.24Volume86,970 shsAverage Volume408,477 shsMarket Capitalization$1.39 billionP/E RatioN/ADividend YieldN/APrice Target$35.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Vericel MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside22.0% Upside$35.50 Price TargetShort InterestBearish12.50% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$1.08 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.26) to $0.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.12 out of 5 starsMedical Sector978th out of 995 stocksBiological Products, Except Diagnostic Industry165th out of 166 stocks 2.3 Analyst's Opinion Consensus RatingVericel has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.50, Vericel has a forecasted upside of 22.0% from its current price of $29.09.Amount of Analyst CoverageVericel has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.50% of the outstanding shares of Vericel have been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.Change versus previous monthShort interest in Vericel has recently increased by 0.85%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVericel does not currently pay a dividend.Dividend GrowthVericel does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VCEL. Previous Next 1.3 News and Social Media Coverage News SentimentVericel has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Vericel this week, compared to 2 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,083,518.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Vericel is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vericel are expected to grow in the coming year, from ($0.26) to $0.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vericel is -80.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vericel is -80.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVericel has a P/B Ratio of 7.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vericel (NASDAQ:VCEL) StockVericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.Read More Receive VCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter. Email Address VCEL Stock News HeadlinesMarch 18, 2023 | americanbankingnews.comVericel (NASDAQ:VCEL) Coverage Initiated at StockNews.comFebruary 28, 2023 | finance.yahoo.comVericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023March 27, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. February 23, 2023 | finance.yahoo.comVericel Corporation (VCEL) Q4 Earnings Surpass EstimatesFebruary 23, 2023 | finance.yahoo.comVericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial GuidanceFebruary 12, 2023 | finance.yahoo.comVericel Corporation (VCEL) Stock Historical Prices & Data - Yahoo FinanceFebruary 9, 2023 | finance.yahoo.comVericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023January 31, 2023 | finance.yahoo.comVericel (NASDAQ:VCEL) shareholders are still up 275% over 5 years despite pulling back 5.7% in the past weekMarch 27, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. January 12, 2023 | finance.yahoo.comVericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?January 10, 2023 | finance.yahoo.comVericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic ProgramJanuary 4, 2023 | finance.yahoo.comVericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023December 29, 2022 | finance.yahoo.comVericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in AdultsNovember 11, 2022 | finance.yahoo.comVericel Third Quarter 2022 Earnings: Misses ExpectationsNovember 10, 2022 | finance.yahoo.comVericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment ConferenceNovember 9, 2022 | finance.yahoo.comVericel Corporation (VCEL) Reports Q3 Loss, Lags Revenue EstimatesNovember 9, 2022 | finance.yahoo.comVericel Reports Third Quarter 2022 Financial ResultsOctober 26, 2022 | finance.yahoo.comVericel to Report Third-Quarter 2022 Financial Results on November 9, 2022October 15, 2022 | benzinga.comCell and Gene Therapy Market Size to Grow by USD 9.97 Bn, Increasing Prevalence of Chronic Diseases to Dr - BenzingaOctober 14, 2022 | streetinsider.comDecibel Therapeutics (DBTX) Appoints Kevin F. McLaughlin to its Board - StreetInsider.comOctober 12, 2022 | streetinsider.comDecibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors - StreetInsider.comOctober 12, 2022 | finance.yahoo.comDecibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors - Yahoo FinanceOctober 10, 2022 | finance.yahoo.comIs it Still Safe to Own Carvana (CVNA) Shares? - Yahoo FinanceOctober 10, 2022 | finance.yahoo.comIs it Still Worthy to Invest in Salesforce (CRM)? - Yahoo FinanceOctober 10, 2022 | finance.yahoo.comShould You Still Consider Buying Meta Platforms (META) Shares? - Yahoo FinanceOctober 10, 2022 | finance.yahoo.comHere’s Why Aristotle Capital Exited Twitter (TWTR) in the Second Quarter - Yahoo FinanceOctober 10, 2022 | seekingalpha.comVericel: Stock Has Fallen, But Not Enough To Make This A Buy (NASDAQ:VCEL) - Seeking AlphaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter. Email Address VCEL Company Calendar Last Earnings2/23/2023Today3/27/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VCEL CUSIPN/A CIK887359 Webwww.vcel.com Phone(617) 588-5555Fax617-588-5554Employees281Year Founded1989Price Target and Rating Average Stock Price Forecast$35.50 High Stock Price Forecast$40.00 Low Stock Price Forecast$31.00 Forecasted Upside/Downside+22.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,710,000.00 Net Margins-10.17% Pretax Margin-9.73% Return on Equity-9.32% Return on Assets-6.64% Debt Debt-to-Equity RatioN/A Current Ratio4.99 Quick Ratio4.56 Sales & Book Value Annual Sales$163.70 million Price / Sales8.38 Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / Book7.12Miscellaneous Outstanding Shares47,360,000Free Float44,901,000Market Cap$1.37 billion OptionableOptionable Beta1.72 Social Links Key ExecutivesDominick C. ColangeloPresident, Chief Executive Officer & DirectorMichael HalpinChief Operating OfficerJoseph A. MaraChief Financial Officer & TreasurerJonathan Mark HopperChief Medical OfficerSean C. FlynnSecretary, Senior Vice President & General CounselKey CompetitorsBioCryst PharmaceuticalsNASDAQ:BCRXRecursion PharmaceuticalsNASDAQ:RXRXIovance BiotherapeuticsNASDAQ:IOVAKymera TherapeuticsNASDAQ:KYMRArcellxNASDAQ:ACLXView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 896 shares on 3/23/2023Ownership: 0.054%Victory Capital Management Inc.Sold 15,126 shares on 3/10/2023Ownership: 0.551%NatixisBought 102,300 shares on 2/24/2023Ownership: 0.217%Macquarie Group Ltd.Sold 179,658 shares on 2/21/2023Ownership: 2.257%Truist Financial CorpSold 6,995 shares on 2/17/2023Ownership: 0.121%View All Insider TransactionsView All Institutional Transactions VCEL Stock - Frequently Asked Questions Should I buy or sell Vericel stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VCEL shares. View VCEL analyst ratings or view top-rated stocks. What is Vericel's stock price forecast for 2023? 4 analysts have issued 1 year target prices for Vericel's stock. Their VCEL share price forecasts range from $31.00 to $40.00. On average, they anticipate the company's stock price to reach $35.50 in the next twelve months. This suggests a possible upside of 22.5% from the stock's current price. View analysts price targets for VCEL or view top-rated stocks among Wall Street analysts. How have VCEL shares performed in 2023? Vericel's stock was trading at $26.34 at the start of the year. Since then, VCEL shares have increased by 10.0% and is now trading at $28.97. View the best growth stocks for 2023 here. When is Vericel's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our VCEL earnings forecast. How were Vericel's earnings last quarter? Vericel Co. (NASDAQ:VCEL) issued its quarterly earnings results on Thursday, February, 23rd. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.10. The biotechnology company had revenue of $52.70 million for the quarter, compared to the consensus estimate of $52.95 million. Vericel had a negative trailing twelve-month return on equity of 9.32% and a negative net margin of 10.17%. The firm's quarterly revenue was up 10.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.09 EPS. What ETFs hold Vericel's stock? ETFs with the largest weight of Vericel (NASDAQ:VCEL) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Syntax Stratified SmallCap ETF (SSLY) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What guidance has Vericel issued on next quarter's earnings? Vericel updated its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $180.00 million-$188.00 million, compared to the consensus revenue estimate of $192.58 million. What is Nick Colangelo's approval rating as Vericel's CEO? 6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Vericel own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA). What is Vericel's stock symbol? Vericel trades on the NASDAQ under the ticker symbol "VCEL." Who are Vericel's major shareholders? Vericel's stock is owned by many different retail and institutional investors. Top institutional shareholders include Conestoga Capital Advisors LLC (4.97%), Fisher Asset Management LLC (3.73%), GW&K Investment Management LLC (2.79%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.49%), Macquarie Group Ltd. (2.26%) and New York State Common Retirement Fund (2.19%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman. View institutional ownership trends. How do I buy shares of Vericel? Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vericel's stock price today? One share of VCEL stock can currently be purchased for approximately $28.97. How much money does Vericel make? Vericel (NASDAQ:VCEL) has a market capitalization of $1.37 billion and generates $163.70 million in revenue each year. The biotechnology company earns $-16,710,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. How many employees does Vericel have? The company employs 281 workers across the globe. How can I contact Vericel? Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.vcel.com. The biotechnology company can be reached via phone at (617) 588-5555, via email at ir@vcel.com, or via fax at 617-588-5554. This page (NASDAQ:VCEL) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.